

Major Blockbuster Drugs Losing Patent in 2018

S. no.	Drug Name	Molecule	Company	2017 Sales in US only (USD Billion)	Indication
1.	Rituxan	rituximab	Roche	\$4.41 billion	Blood cancers, rheumatoid arthritis
2.	Neulasta	pegfilgrastim	Amgen	\$3.93 billion	White blood cell booster
3.	Lyrica	pregabalin	Pfizer	\$3.46 billion	Nerve and muscle pain
4.	Advair	fluticasone and salmeterol	GlaxoSmithKline	\$2.23 billion	Asthma and COPD
5.	Xolair	omalizumab	Roche/Novartis	\$1.83 billion	Allergic asthma and chronic idiopathic urticaria
6.	Epogen/Procrit	epoetin alfa	Amgen/J&J	\$1.77 billion	Anaemia
7.	Restasis	Cyclosporine Ophthalmic Emulsion	Allergan	\$1.41 billion	Dry eye
8.	Cialis	tadalafil	Eli Lilly	\$1.359 billion	Erectile dysfunction
9.	Sensipar	cinacalcet	Amgen	\$1.347 billion	Calcium reducer
10.	Zytiga	abiraterone acetate	Johnson & Johnson	\$1.228 billion	Prostate cancer

Source

Disclaimer: The information in this presentation was compiled from sources believed to be reliable for informational purposes only. We do not guarantee the accuracy of this information or any results and further assume no liability in connection with this publication, including any information, methods or safety suggestions contained herein. For the latest updates pertaining to this compilation visit the relevant website.

For any Feedback or suggestion mail at: info@pharmastate.com

Weblink – <https://pharmastate.com/>

Applink - <https://goo.gl/mS8Lr7>